With Pfizer set this month to launch its biosimilar version of AbbVie’s mega-blockbuster Humira, the company has expanded its partnership with Samsung Biologics, which will produce biosimilars for the pharma giant at its sprawling complex in South Korea.
Samsung said on Monday that Pfizer had added $486 million to two biosimilar production agreements the companies had made earlier this year.
Pfizer acknowledged the “strategic partnership” for the company’s “multi-product biosimilars portfolio,” but provided no further comment.
